Lazard Asset Management LLC Atea Pharmaceuticals, Inc. Transaction History

Lazard Asset Management LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$3.0 - $3.79 $8,859 - $11,191	-2,953 Reduced 56.24%	2,298 $6,000
Q1 2023 May 15, 2023	SELL	$3.0 - $4.97 $14,574 - $24,144	-4,858 Reduced 48.06%	5,251 $17,000
Q3 2022 Nov 14, 2022	SELL	$5.49 - $8.79 $26,631 - $42,640	-4,851 Reduced 32.43%	10,109 $57,000
Q2 2022 Aug 09, 2022	BUY	$5.33 - $8.18 $21,597 - $33,145	4,052 Added 37.15%	14,960 $106,000
Q1 2022 May 13, 2022	BUY	$5.5 - $9.19 $12,639 - $21,118	2,298 Added 26.69%	10,908 $78,000
Q4 2021 Feb 09, 2022	BUY	$7.67 - $44.59 $66,038 - $383,919	8,610 New	8,610 $76,000

112

52.4M

900

126K

Ticker AVIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,258,600
Market Cap $271M
Description
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...

Get notified when there are updates to the investment portfolio of Lazard Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Lazard Asset Management LLC with notifications on news.